Filing Details

Accession Number:
0001628280-19-004178
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-04-10 21:58:47
Reporting Period:
2019-04-08
Accepted Time:
2019-04-10 21:58:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1397702 Silk Road Medical Inc SILK Surgical & Medical Instruments & Apparatus (3841) 208777622
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1414561 Warburg Pincus X, L.p. C/O Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
No No Yes No
1414564 L.p. Gp X Pincus Warburg C/O Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
No No Yes No
1414565 Warburg Pincus Private Equity X, L.p. C/O Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
No No Yes No
1451560 Warburg Pincus X Partners, L.p. C/O Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
No No Yes No
1621224 Warburg Pincus Partners Gp Llc C/O Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
No No Yes No
1621242 Warburg Pincus Partners, L.p. C/O Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
No No Yes No
1621874 Wpp Gp Llc C/O Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
No No Yes No
1770767 Wp X Finance, L.p. C/O Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
No No Yes No
1770772 Wpx Gp, L.p. C/O Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-04-08 13,079,728 $0.00 13,099,629 No 4 C Direct
Common Stock Disposition 2019-04-08 900,000 $20.00 12,199,629 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2019-04-08 5,637,492 $0.00 5,637,492 $0.00
Common Stock Series C Preferred Stock Disposition 2019-04-08 5,904,180 $0.00 5,904,180 $0.00
Common Stock Series C Preferred Stock Warrant (Right to buy) Disposition 2019-04-08 1,071,902 $0.00 1,071,902 $6.11
Common Stock Series C Preferred Stock Warrant (Right to buy) Disposition 2019-04-08 1,074,072 $0.00 1,074,072 $6.11
Common Stock Series C Preferred Stock Warrant (Right to buy) Disposition 2019-04-08 34,291 $0.00 34,291 $6.11
Common Stock Series C Preferred Stock Warrant (Right to buy) Disposition 2019-04-08 34,361 $0.00 34,361 $6.11
Common Stock Series C Preferred Stock Acquisiton 2019-04-08 2,145,974 $0.00 2,145,974 $0.00
Common Stock Series C Preferred Stock Acquisiton 2019-04-08 68,652 $0.00 68,652 $0.00
Common Stock Series C Preferred Stock Disposition 2019-04-08 655,596 $0.00 655,596 $0.00
Common Stock Series C Preferred Stock Disposition 2019-04-08 20,974 $0.00 20,974 $0.00
Common Stock Series C Preferred Stock Disposition 2019-04-08 1,538,056 $0.00 1,538,056 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 2022-08-07 No 4 X Direct
0 2023-10-13 No 4 X Direct
0 2022-08-07 No 4 X Direct
0 2023-10-13 No 4 X Direct
2,145,974 No 4 X Direct
68,652 No 4 X Direct
1,490,378 No 4 J Direct
47,678 No 4 J Direct
0 No 4 C Direct
Footnotes
  1. The Series B Preferred Stock and Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
  2. 12,693,546 of these shares are held by WP X Finance, L.P. ("WP X Finance") and 406,083 of these shares are held by Warburg Pincus X Partners, L.P. ("WPXP"). The total of 13,099,629 shares beneficially owned is comprised of (i) 19,901 shares of Common Stock held prior to the date hereof (ii) 5,637,492 shares of Common Stock issued upon conversion of Series B Preferred Stock held prior to the date hereof, (iii) 5,904,180 shares of Common Stock issued upon conversion of Series C Preferred Stock held prior to the date hereof, and (iv) 1,538,056 shares of Common Stock issued upon conversion of Series C Preferred Stock issued pursuant to the net exercise of warrants, as detailed in footnotes (9), (12), (13) and (15).
  3. WPX GP, L.P., a Delaware limited partnership ("WPX GP"), is the managing general partner of WP X Finance. Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X"), is the general partner of WPX GP. Warburg Pincus X, L.P., a Delaware limited partnership ("WPX LP"), is the general partner of WPX and WPXP. Warburg Pincus X GP L.P., a Delaware limited partnership ("WP X GP LP"), is the general partner of WPX LP. WPP GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WP X GP LP. Warburg Pincus Partners, L.P., a Delaware limited partnership ("WP Partners"), is the managing member of WPP GP. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WP Partners GP"), is the general partner of WP Partners.
  4. (continuation from footnote 3) Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WP Partners GP. Charles R. Kaye and Joseph P. Landy are each Managing General Partners of WP and may each be deemed to control the Warburg Pincus entities. Messrs. Kaye and Landy disclaim beneficial ownership of all shares held by the Warburg Pincus entities.
  5. 872,100 shares were sold by WP X Finance, and 27,900 shares were sold by WPXP, each in connection with the exercise of the underwriter's overallotment option pursuant to the Issuer's initial public offering of Common Stock.
  6. 11,821,446 of these shares are held by WP X Finance and 378,183 of these shares are held by WPXP.
  7. 5,462,731 of these shares are held by WP X Finance and 174,761 of these shares are held by WPXP.
  8. 5,721,152 of these shares are held by WP X Finance and 183,028 of these shares are held by WPXP.
  9. WP X Finance exercised a warrant to purchase 1,071,902 shares of the Issuer's Series C Preferred Stock at a per share exercise price of $6.11. WP X Finance paid the exercise price on a cashless basis, resulting in the Issuer withholding 327,467 of the warrant shares to pay the exercise price and issued to WP X Finance the remaining 744,435 shares.
  10. All of the shares subject to the warrant are fully exercisable as of the date hereof.
  11. This warrant is held by WP X Finance.
  12. WP X Finance exercised a warrant to purchase 1,074,072 shares of the Issuer's Series C Preferred Stock at a per share exercise price of $6.11. WP X Finance paid the exercise price on a cashless basis, resulting in the Issuer withholding 328,129 of the warrant shares to pay the exercise price and issued to WP X Finance the remaining 745,943 shares.
  13. WPXP exercised a warrant to purchase 34,291 shares of the Issuer's Series C Preferred Stock at a per share exercise price of $6.11. WPXP paid the exercise price on a cashless basis, resulting in the Issuer withholding 10,476 of the warrant shares to pay the exercise price and issued to WPXP the remaining 23,815 shares.
  14. This warrant is held by WPXP.
  15. WPXP exercised a warrant to purchase 34,361 shares of the Issuer's Series C Preferred Stock at a per share exercise price of $6.11. WPXP paid the exercise price on a cashless basis, resulting in the Issuer withholding 10,498 of the warrant shares to pay the exercise price and issued to WPXP the remaining 23,863 shares.
  16. These shares are held by WP X Finance.
  17. These shares are held by WPXP.
  18. These shares are comprised of 327,467 shares and 328,129 shares withheld by the Issuer pursuant to the net exercise of warrants, as detailed in footnotes (9) and (12).
  19. These shares are comprised of 10,476 shares and 10,498 shares withheld by the Issuer pursuant to the net exercise of warrants, as detailed in footnotes (13) and (15).
  20. Prior to conversion to Common Stock, these shares are comprised of 1,490,378 shares held by WPX Finance and 47,678 shares held by WPXP.